OTCM
CUBT
Market cap7mUSD
Jul 15, Last price
0.01USD
1D
1.51%
1Q
-31.91%
Jan 2017
4,275.00%
IPO
-99.13%
Name
Curative Biotechnology Inc
Chart & Performance
Profile
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1,933 | 4,428 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,933) | (4,428) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 1,175 | ||||||||
Tax Rate | |||||||||
NOPAT | (1,933) | (5,603) | |||||||
Net income | (5,817) 3.79% | (5,605) 4.95% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 542 | 268 | |||||||
BB yield | -3.85% | -2.35% | |||||||
Debt | |||||||||
Debt current | 2,258 | 1,071 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 2,202 | 1,012 | |||||||
Cash flow | |||||||||
Cash from operating activities | (487) | (1,536) | |||||||
CAPEX | (77) | ||||||||
Cash from investing activities | (14) | (77) | |||||||
Cash from financing activities | 498 | 1,001 | |||||||
FCF | (2,397) | (2,255) | |||||||
Balance | |||||||||
Cash | 56 | 59 | |||||||
Long term investments | |||||||||
Excess cash | 56 | 59 | |||||||
Stockholders' equity | (38,137) | (32,552) | |||||||
Invested Capital | 37,253 | 31,225 | |||||||
ROIC | |||||||||
ROCE | 218.56% | 333.60% | |||||||
EV | |||||||||
Common stock shares outstanding | 662,161 | 572,010 | |||||||
Price | 0.02 6.50% | 0.02 -62.96% | |||||||
Market cap | 14,104 23.28% | 11,440 -57.71% | |||||||
EV | 16,308 | 12,452 | |||||||
EBITDA | (1,843) | (4,420) | |||||||
EV/EBITDA | |||||||||
Interest | 1,357 | 1,170 | |||||||
Interest/NOPBT |